| 32 | Humans |
| 17 | Plasmodium falciparum |
| 16 | Female |
| 14 | Malaria |
| 13 | Chloroquine |
| 12 | Male |
| 10 | Animals |
| 8 | Human |
| 7 | Treatment Outcome |
| 7 | Lung |
| 7 | Child |
| 7 | Antimalarials (pharmacology) |
| 7 | Antimalarial |
| 6 | Plasmodium falciparum (drug effects) |
| 6 | Middle Aged |
| 6 | Hydroxychloroquine |
| 6 | Chloroquine (pharmacology) |
| 6 | Aged |
| 6 | Adult |
| 5 | Treatment |
| 5 | Case study |
| 5 | Autophagy |
| 5 | Antimalarials (chemistry) |
| 4 | rheumatoid arthritis |
| 4 | ferroquine |
| 4 | Tomography, X-Ray Computed |
| 4 | Retrospective Studies |
| 4 | Q fever |
| 4 | Mutation |
| 4 | Infant |
| 4 | In vitro |
| 4 | Cytotoxicity |
| 4 | Chemotherapy |
| 4 | Cell Line, Tumor |
| 3 | malaria |
| 3 | chloroquine |
| 3 | cardiovascular disease |
| 3 | autophagy |
| 3 | Sarcoidosis |
| 3 | Pulmonary Surfactant-Associated Protein C (genetics) |
| 3 | Plasmodium |
| 3 | Plant origin |
| 3 | Parasiticide |
| 3 | Oxygen Inhalation Therapy |
| 3 | Molecular Structure |
| 3 | Lung Diseases, Interstitial (therapy) |
| 3 | Lung Diseases, Interstitial (genetics) |
| 3 | Hypoxia |
| 3 | Endocytosis |
| 3 | Cholesterol |
| 3 | Cells, Cultured |
| 3 | Cell Line |
| 3 | Biological activity |
| 3 | Antimalarials |
| 3 | Antimalarials (isolation & purification) |
| 3 | Adolescent |
| 3 | Acute |
| 2 | tabagisme passif |
| 2 | sarcoid bone lesions |
| 2 | resistance |
| 2 | primary Sjögren’s syndrome |
| 2 | nicotine passive exposure |
| 2 | mechanism of action |
| 2 | management |
| 2 | hydroxychloroquine |
| 2 | hair analysis |
| 2 | gene therapy |
| 2 | drug monitoring |
| 2 | drug candidate |
| 2 | calcaneus |
| 2 | antimalarials |
| 2 | antimalarial activity |
| 2 | analyse de cheveux |
| 2 | Toxicity |
| 2 | Time Factors |
| 2 | Taste (physiology) |
| 2 | Surfactant |
| 2 | Skin |
| 2 | Rheumatoid arthritis |
| 2 | Respiratory distress |
| 2 | Resistance |
| 2 | Recurrence |
| 2 | Receptors, G-Protein-Coupled (metabolism) |
| 2 | Receptors, G-Protein-Coupled (agonists) |
| 2 | Rats |
| 2 | RA, rheumatoid arthritis |
| 2 | Quinine |
| 2 | Pulmonary surfactant |
| 2 | Pulmonary Alveolar Proteinosis (genetics) |
| 2 | Prognosis |
| 2 | Plant Extracts (pharmacology) |
| 2 | Pharmacognosy |
| 2 | Pedigree |
| 2 | Pediatrics |
| 2 | Parasiticid |
| 2 | Nitrogen heterocycle |
| 2 | Microbial Sensitivity Tests |
| 2 | Mice |
| 2 | Methylene blue |
| 2 | Medicinal plant |
| 2 | MALARIA |
| 2 | Lung Neoplasms (pathology) |
| 2 | Lung Diseases, Interstitial (diagnostic imaging) |
| 2 | Hydroxychloroquine (therapeutic use) |
| 2 | Glucocorticoids (therapeutic use) |
| 2 | Gene transfer |
| 2 | Gene therapy |
| 2 | Gabon |
| 2 | Fatal Outcome |
| 2 | Edema |
| 2 | Drug resistance |
| 2 | Drug Screening Assays, Antitumor |
| 2 | Drug Resistance |
| 2 | Diagnosis |
| 2 | Corticosteroid |
| 2 | Compliance |
| 2 | Cell line |
| 2 | Cell Proliferation (drug effects) |
| 2 | Bronchoscopy |
| 2 | Bronchoalveolar Lavage Fluid (chemistry) |
| 2 | Biopsy |
| 2 | Association |
| 2 | Arthritis |
| 2 | Artemisinin |
| 2 | Antiplasmodial |
| 2 | Antineoplastic Agents, Phytogenic (pharmacology) |
| 2 | Antineoplastic Agents, Phytogenic (chemistry) |
| 2 | Antimicrobial |
| 2 | Amodiaquine |
| 2 | Alzheimer’s disease |
| 2 | Aged, 80 and over |
| 2 | Age of Onset |
| 2 | Adherence |
| 2 | AMODIAQUINE |
| 2 | ACR, American College of Rheumatology |
| 1 | β2 microglobulin |
| 1 | β-hematin |
| 1 | β-carbolines |
| 1 | Β-secretase modulators |
| 1 | |
| 1 | xanthones |
| 1 | viruses |
| 1 | vertebral osteomyelitis |
| 1 | vascular graft |
| 1 | urticarial vasculitis |
| 1 | tumour necrosis factor |
| 1 | tumor necrosis factor |
| 1 | tricyclic |
| 1 | treatment |
| 1 | traditional medicine |
| 1 | therapy |
| 1 | systemic vasculitis |
| 1 | systemic lupus erythematosus |
| 1 | syntaxin-17 |
| 1 | synaptosome-associated protein of 29 kDa |
| 1 | surveillance thérapeutique |
| 1 | surveillance thé |
| 1 | subcutaneous adipose tissue |
| 1 | subcellular imaging |
| 1 | src-Family Kinases (metabolism) |
| 1 | spirooxindoles |
| 1 | speciophylline |
| 1 | soins de santé primaires |
| 1 | silicosis |
| 1 | silicose |
| 1 | signaling |
| 1 | severe falciparum malaria |
| 1 | sensible stage |
| 1 | seizures |
| 1 | ruthenocifens |
| 1 | rodent Plasmodium |
| 1 | rituximab |
| 1 | reversal agent |
| 1 | retinal toxicity |
| 1 | replication |
| 1 | receptor-mediated endocytosis |
| 1 | reactive species |
| 1 | rapeutique |
| 1 | rapamycin |
| 1 | quinoline resistance |
| 1 | quinidine like effect |
| 1 | pédiatrie |
| 1 | pulmonary edema |
| 1 | primary immune deficiency |
| 1 | primary health care |
| 1 | polyplexes |
| 1 | polymyositis |
| 1 | podocyte |
| 1 | pneumoconiosis |
| 1 | pneumoconiose |
| 1 | plasmid |
| 1 | piperazine |
| 1 | picornavirus |
| 1 | phé |
| 1 | phytotherapy |
| 1 | phenobarbital |
| 1 | phenanthroline |
| 1 | pharmacology |
| 1 | pediatrics |
| 1 | paludisme grave |
| 1 | pSS, primary Sjögren’s syndrome |
| 1 | pLK, poly-l-lysine. |
| 1 | pH-sensitive |
| 1 | obesity |
| 1 | non hodgkin lymphoma |
| 1 | nobarbital |
| 1 | neurotrophins |
| 1 | neurodegeneration |
| 1 | nanoparticles |
| 1 | myocarditis |
| 1 | mortalité |
| 1 | mortality |
| 1 | morbidité |
| 1 | morbidity |
| 1 | monoclonal antibody |
| 1 | methylene blue |
| 1 | metallodrug activity |
| 1 | mature schizonts |
| 1 | magnetic resonance imaging |
| 1 | mAMSA, 4′-(9-acridinylamino)-methanesulfon-m-anisidide |
| 1 | lysosome |
| 1 | lung |
| 1 | luciferase |
| 1 | liposome |
| 1 | lipids |
| 1 | kidney |
| 1 | intracellular traffic |
| 1 | intoxication |
| 1 | interleukin-6 |
| 1 | infected abdominal aortic aneurysm |
| 1 | increasing dose |
| 1 | in vitro |
| 1 | immune response |
| 1 | hydroxychloroquine blood concentration |
| 1 | human t-lymphotropic virus 1 |
| 1 | high-mobility group proteins |
| 1 | hemicatenane |
| 1 | heart |
| 1 | haem. |
| 1 | granulomatous disease |
| 1 | glycoplexes |
| 1 | glycoconjugates |
| 1 | glutathione |
| 1 | glomerulus |
| 1 | free merozoites |
| 1 | fractionation |
| 1 | fibrosis |
| 1 | ferrocifens |
| 1 | extracellular matrix |
| 1 | exchange transfusion |
| 1 | enterovirus |
| 1 | enterovirus A71 |
| 1 | endocytosis |
| 1 | electropermeabilisation |
| 1 | early rheumatoid arthritis |
| 1 | drugs of abuse |
| 1 | drug-binding proteins |
| 1 | drug uptake |
| 1 | drug resistance |
| 1 | drug interactions |
| 1 | drug delivery |
| 1 | drogues |
| 1 | doxycycline |
| 1 | dmards (synthetic) |
| 1 | disease activity |
| 1 | dermatomyositis |
| 1 | dendritic cells |
| 1 | decision tree |
| 1 | deca-2E 6Z 8E-trienoic acid isobutylamide |
| 1 | cytotoxicity |
| 1 | cutaneous lupus erythematosus |
| 1 | connectivite |
| 1 | connective tissue diseases |
| 1 | colorectal cancer |
| 1 | collagen |
| 1 | chloroquine gels |
| 1 | child |
| 1 | chemosensitizer |
| 1 | cell culture |
| 1 | bronchoalveolar lavage fluid |
| 1 | bleomycin |
| 1 | bioorganometallics |
| 1 | bioorganometallic chemistry |
| 1 | autolysosome |
| 1 | autoimmunity |
| 1 | asthma |
| 1 | arthritis |
| 1 | apoptosis |
| 1 | antitrypanosomal activity |
| 1 | antirheumatic agents |
| 1 | antiplasmodial activity |
| 1 | antiparasitic agents |
| 1 | antimalarial drug |
| 1 | antimalarial drug resistance |
| 1 | antileishmanial activity |
| 1 | antidepressant |
| 1 | antibody deficiency |
| 1 | anti-SSA/SSB |
| 1 | amyloid precursor protein |
| 1 | alveolitis, extrinsic allergic |
| 1 | alternative DNA conformations |
| 1 | alkylamides |
| 1 | adalimumab |
| 1 | Young adult |
| 1 | Xanthones (pharmacology) |
| 1 | Xanthones (chemistry) |
| 1 | XMEA |
| 1 | Withania frutescens |
| 1 | Whipple Disease (epidemiology) |
| 1 | Whipple Disease (drug therapy) |
| 1 | Whipple Disease (cerebrospinal fluid) |
| 1 | Wall |
| 1 | Virus Replication |
| 1 | Viral entry |
| 1 | Viral Nonstructural Proteins |
| 1 | Vietnam |
| 1 | Vasolin containing protein |
| 1 | Vascular infection |
| 1 | VCP |
| 1 | Uroporphyrins |
| 1 | Upper limb |
| 1 | Ubiquitin (metabolism) |
| 1 | Two-Hybrid System Techniques |
| 1 | Tumor |
| 1 | Tumor cell susceptibility |
| 1 | Tsc1 |
| 1 | Tropheryma whipplei |
| 1 | Tropheryma (pathogenicity) |
| 1 | Tropheryma (drug effects) |
| 1 | Triterpenes (pharmacology) |
| 1 | Triterpenes (isolation & purification) |
| 1 | Triterpenes (chemistry) |
| 1 | Triglycerides |
| 1 | Trichloromethyl goup |
| 1 | Treatment efficiency |
| 1 | Translation elongation |
| 1 | Traditional remedy |
| 1 | Traditional medicine |
| 1 | Tracheostomy |
| 1 | Toxins |
| 1 | Tomography, X-Ray Computed (methods) |
| 1 | Thyroid Nuclear Factor 1 (genetics) |
| 1 | Therapeutic drug monitoring |
| 1 | Therapeutic agent |
| 1 | Th17-mediated disease |
| 1 | Tetralone |
| 1 | Terpenes (pharmacology) |
| 1 | Terpenes (isolation & purification) |
| 1 | Terpenes (chemistry) |
| 1 | Temperature |
| 1 | Taste |
| 1 | TRIS |
| 1 | TNF |
| 1 | TNF, tumour necrosis factor |
| 1 | TGF-BMP: transforming growth factor-bone morphogenic protein ARTICLE HISTORY KEYWORDS ATG7 |
| 1 | TB, tuberculosis |
| 1 | T-Lymphocytes, Cytotoxic (immunology) |
| 1 | Systemic |
| 1 | Systemic sclerosis |
| 1 | Systemic lupus erythematosus |
| 1 | Synovitis |
| 1 | Symptomatology |
| 1 | Survival |
| 1 | Suicide |
| 1 | Strychnobrasiline |
| 1 | Strychnine (pharmacology) |
| 1 | Structure-Activity Relationship |
| 1 | Structure activity relation |
| 1 | Structural analysis |
| 1 | Streric block oligonucleotide analogues |
| 1 | Stomatocytogenesis |
| 1 | Stereoisomerism |
| 1 | Stem |
| 1 | Status Epilepticus/diagnostic imaging/drug therapy/*etiology |
| 1 | Spondyloarthritis |
| 1 | Splice correction and cancer |
| 1 | Sjögren's syndrome |
| 1 | Sjögren syndrome |
| 1 | Six membered ring |
| 1 | Signal transducer and activator of transcription 3 |
| 1 | Signal Transduction |
| 1 | Signal Transduction (physiology) |
| 1 | Signal Transduction (drug effects) |
| 1 | Siblings |
| 1 | Severity score |
| 1 | Severe Malaria |
| 1 | Sequestosome-1 Protein |
| 1 | Sepiolite |
| 1 | Senegal |
| 1 | Selectivity |
| 1 | Selectivity index |
| 1 | Secondary prevention |
| 1 | Screening |
| 1 | Scleroderma |
| 1 | Scintigraphy |
| 1 | ScAT: subcutaneous adipose tissue |
| 1 | Sarcoidosis (genetics) |
| 1 | Sarcoidosis (drug therapy) |
| 1 | Saponin B |
| 1 | SYBR green |
| 1 | SULFADOXINE-PYRIMETHAMINE |
| 1 | STAT3 Transcription Factor (metabolism) |
| 1 | SSZ, sulfasalazine |
| 1 | SSA/SSB, Sjögren’s syndrome antigen A or B |
| 1 | SOUTHEAST-ASIA |
| 1 | SNARE |
| 1 | SLEDAI, SLE disease activity index |
| 1 | SLE, systemic lupus erythematosus |
| 1 | SJC, swollen joint count |
| 1 | SIR, standardised incidence ratio |
| 1 | SEER, Surveillance, Epidemiology, and End Results |
| 1 | SDS, sodium dodecyl sulfate |
| 1 | SAE, serious adverse event |
| 1 | Roscovitine |
| 1 | Rituximab |
| 1 | Risk Factors |
| 1 | Rheumatoid |
| 1 | Rheedia acuminata |
| 1 | Respiratory tract |
| 1 | Respiratory disease |
| 1 | Respiratory Tract Diseases (metabolism) |
| 1 | Respiratory System (metabolism) |
| 1 | Respiratory Function Tests (methods) |
| 1 | Respiratory Distress Syndrome, Newborn (pathology) |
| 1 | Respiratory Distress Syndrome, Newborn (genetics) |
| 1 | Respiratory Distress Syndrome, Newborn (etiology) |
| 1 | Respiratory Distress Syndrome, Newborn (complications) |
| 1 | Respiratory Distress Syndrome, Adult (therapy) |
| 1 | Respiratory Distress Syndrome, Adult (genetics) |
| 1 | Respiratory Distress Syndrome, Adult (etiology) |
| 1 | Respiration, Artificial |
| 1 | Research Design |
| 1 | Regression |
| 1 | Redux |
| 1 | Reduced glutathione- O-phthalaldehyde |
| 1 | Recommendations |
| 1 | Receptors, G-Protein-Coupled (physiology) |
| 1 | Receptors, G-Protein-Coupled (drug effects) |
| 1 | Receptors, Cell Surface (physiology) |
| 1 | Receptors, Cell Surface (metabolism) |
| 1 | Receptors, Cell Surface (drug effects) |
| 1 | Receptors, Cell Surface (agonists) |
| 1 | Rat |
| 1 | Raqaypampeños |
| 1 | Raptor |
| 1 | Radiography |
| 1 | Radiography, Thoracic |
| 1 | Radical scavenging |
| 1 | Quinoline derivatives |
| 1 | Quechua |
| 1 | Qc-SNARE Proteins |
| 1 | Qb-SNARE Proteins |
| 1 | Qa-SNARE Proteins |
| 1 | Q Fever/complications/*diagnosis/drug therapy |
| 1 | Périnatalité |
| 1 | Pyrrolo[1 |
| 1 | Pyrostria major |
| 1 | Pyrazoles (therapeutic use) |
| 1 | Pyomyositis |
| 1 | Purvalanol |
| 1 | Pulmonary hypertension |
| 1 | Pulmonary Surfactants (metabolism) |
| 1 | Pulmonary Surfactant-Associated Protein C (analysis) |
| 1 | Pulmonary Surfactant-Associated Protein B (genetics) |
| 1 | Pulmonary Surfactant-Associated Protein B (deficiency) |
| 1 | Pulmonary Fibrosis (therapy) |
| 1 | Pulmonary Fibrosis (diagnosis) |
| 1 | Pulmonary Edema (pathology) |
| 1 | Pulmonary Edema (complications) |
| 1 | Pulmonary Alveolar Proteinosis (diagnosis) |
| 1 | Pulmonary Alveolar Proteinosis (complications) |
| 1 | Public health |
| 1 | Psidium acutangulum |
| 1 | Pseudomonas Infections (etiology) |
| 1 | Pseudomonas Infections (diagnostic imaging) |
| 1 | Protein Interaction Mapping |
| 1 | Protein C |
| 1 | Protein Binding |
| 1 | Proteasome |
| 1 | Proteasome Endopeptidase Complex (metabolism) |
| 1 | Pro-drug |
| 1 | Primary antiphospholipid syndrome |
| 1 | Primary Sjögren's syndrome |
| 1 | Porphyria Cutanea Tarda |
| 1 | Porifera (chemistry) |
| 1 | Polymyalgia Rheumatica |
| 1 | Polylysine |
| 1 | Polycythemia Vera (genetics) |
| 1 | Polycythemia Vera (drug therapy) |
| 1 | Poisoning |
| 1 | Pneumopathy |
| 1 | Pneumonia, Pneumocystis (etiology) |
| 1 | Pneumonia, Pneumocystis (diagnostic imaging) |
| 1 | Pneumonia, Bacterial (etiology) |
| 1 | Pneumonia, Bacterial (diagnostic imaging) |
| 1 | Pneumology |
| 1 | Platinum |
| 1 | Plasmodium falciparum (metabolism) |
| 1 | Plasmodium berghei |
| 1 | Plants, Medicinal (chemistry) |
